Olacent 100 mg (Tablet)
Unit Price: ৳ 250.00 (2 x 10: ৳ 5,000.00)
Strip Price: ৳ 2,500.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Olaparib |
| Company | Incepta pharmaceuticals ltd |
| Also available as |
Title
Olaparib Capsules
Categories
- Cancer Treatment
- Pharmacology
- Dosage
- Drug Interaction
- Contraindications
- Side Effects
- Pregnancy & Lactation
- Precautions & Warnings
- Overdose Effects
- Therapeutic Class
- Storage Conditions
Indications
- Breast Cancer treatment in adult patients
- Ovarian Cancer maintenance treatment in adult patients
Pharmacology
- Mode of Action: Inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes
- Absorption: Rapid absorption with peak plasma concentrations achieved between 1 to 3 hours after dosing
- Distribution: Mean apparent volume of distribution at steady state of 167 +/- 196 L
- Metabolism: Primarily metabolized by CYP3A4/5 enzymes
- Excretion: Mean terminal plasma half-life of 11.9 +/- 4.8 hours
Dosage & Administration
- Recommended Dose: 400 mg taken orally twice daily
- Dosage Modifications: Consider interruption or dose reduction for adverse reactions
- Dose Modifications for Use with CYP3A Inhibitors: Adjust Olaparib dose based on CYP3A inhibition level
- Dose Modifications for Patients with Renal Impairment: Adjust dose based on the degree of renal impairment
- Pediatric Use: Safety and efficacy not established in pediatric patients
Interaction
- Anticancer Agents: Potentiation and prolongation of myelosuppressive toxicity
- Drugs That May Increase Olaparib Plasma Concentrations: Co-administration with CYP3A inhibitors
- Drugs That May Decrease Olaparib Plasma Concentrations: Co-administration with CYP3A inducers
Contraindications
Hypersensitivity to Olaparib or any ingredient in the formulation
Side Effects
- Common Serious Adverse Reactions:
- Anemia
- Dermatitis
- Neutrophil count decrease
- Platelet count decrease
- Percentage of patients who permanently discontinued Olaparib due to adverse events: 4.9% in Olaparib arm, 7.7% in chemotherapy arm
Pregnancy & Lactation
- Pregnancy: May cause fetal harm
- Nursing Mothers: Unknown excretion in human milk, weigh benefits versus risks for nursing mothers
Precautions & Warnings
- Myelodysplastic Syndrome/Acute Myeloid Leukemia: Incidence in patients treated with Olaparib monotherapy
- Pneumonitis: Occurrences in patients treated with Olaparib, prompt assessment and discontinuation if confirmed
Overdose Effects
No specific treatment, follow general supportive measures and treat symptomatically
Therapeutic Class
Targeted Cancer Therapy
Storage Conditions
Store below 30°C, protect from light, keep out of the reach of children